Int J Thyroidol.  2020 Nov;13(2):128-141. 10.11106/ijt.2020.13.2.128.

Ultrasound-Guided Percutaneous Ethanol Ablation for the Management of Recurrent Thyroid Cancer: Evaluation of Efficacy and Impact on Disease Course

• Tofé S
• Argüelles I
• Serra G
• García H
• Barcelo A
• Pereg V

• KMID: 2509191
• DOI: http://doi.org/10.11106/ijt.2020.13.2.128

Abstract

Background and Objectives
Neck recurrences of thyroid cancer are frequently detected in routine ultrasound (US) follow-up. Broad management of these lesions may include active surveillance, surgery or local percutaneous techniques, but for the latter, little is known about impact on long-term follow-up and need of subsequent radioactive iodine (RAI) therapy.
Materials and Methods
42 patients underwent US-guided ethanol ablation (EA) over 71 thyroid bed or lymph node confirmed recurrences. All volume reduction ＞50%, absence of power Doppler signal and fine needle aspiration (FNA) washout thyroglobulin (Tg) value ＜1 ng/mL should be present to consider a complete ablation. Patients with TNM stage I-II, ≤2 lesions and/or baseline plasma TSH-suppressed Tg level ＜0.2 ng/mL did not undergo post-EA RAI therapy. Post-EA plasma Tg values were compared to baseline in patients with and without subsequent RAI therapy.
Results
62 lesions (87.32%) achieved a complete ablation after a mean follow-up of 40.5 months (range, 12-73). Four treated lesions (5.63%) recurred (3/39 and 1/32 in patients with and without subsequent RAI therapy), and 7 patients (16.66%) developed new recurrences throughout follow-up (5/19 and 2/23 with and without RAI therapy). Both plasma TSH-suppressed and TSH-stimulated Tg levels descended after EA in both groups, and 17/38 (44.73%) patients achieved a TSH-suppressed Tg ＜0.2 ng/mL, with no differences between both groups of patients. All EA procedures were conducted safely without serious or persistent side effects.
Conclusion
Successful EA were achieved safely in 87.32% of patients with recurrent thyroid cancer, with a positive effect on systemic disease as reflected by plasma post-EA Tg levels. A subset of patients with TNM stage III, ≤2 lesions and/or low pre-EA plasma Tg levels may not need subsequent RAI therapy after successful ablation. Overall, EA is an effective and balanced therapy for selected patients with neck recurrent thyroid cancer as an alternative to surgery.

Keyword

Ultrasound guided ethanol ablation; Recurrent thyroid cancer; Low risk papillary cancer

Reference

References

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. 2001; Cancer statistics, 2001. CA Cancer J Clin. 51(1):15–36. DOI: 10.3322/canjclin.51.1.15. PMID: 11577478.

2. Sherman SI. 2003; Thyroid carcinoma. Lancet. 361(9356):501–11. DOI: 10.1016/S0140-6736(03)12488-9. PMID: 12583960.

3. Guth S, Theune U, Aberle J, Galach A, Bamberger CM. 2009; Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 39(8):699–706. DOI: 10.1111/j.1365-2362.2009.02162.x. PMID: 19601965.

4. Leenhardt L, Bernier MO, Boin-Pineau MH, Conte Devolx B, Marechaud R, Niccoli-Sire P, et al. 2004; Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 150(2):133–9. DOI: 10.1530/eje.0.1500133. PMID: 14763910.

5. Davies L, Welch HG. 2014; Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 140(4):317–22. DOI: 10.1001/jamaoto.2014.1. PMID: 24557566.

6. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2016; 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Associa-tion guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26(1):1–133. DOI: 10.1089/thy.2015.0020. PMID: 26462967. PMCID: PMC4739132.

7. Benbassat CA, Mechlis-Frish S, Hirsch D. 2006; Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg. 30(6):1088–95. DOI: 10.1007/s00268-005-0472-4. PMID: 16736341.

8. Schmidbauer B, Menhart K, Hellwig D, Grosse J. 2017; Differen-tiated thyroid cancer-treatment: state of the art. Int J Mol Sci. 18(6):1292. DOI: 10.3390/ijms18061292. PMID: 28629126. PMCID: PMC5486113.

9. Aschebrook-Kilfoy B, Schechter RB, Shih YC, Kaplan EL, Chiu BC, Angelos P, et al. 2013; The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev. 22(7):1252–9. DOI: 10.1158/1055-9965.EPI-13-0242. PMID: 23677575.

10. Cady B, Rossi R. 1988; An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 104(6):947–53. DOI: 10.1016/S0039-6060(98)70034-0. PMID: 3194846.

11. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. 1993; Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 114(6):1050–7. discussion 7–8. PMID: 8256208.

12. Uchida H, Imai T, Kikumori T, Hayashi H, Sato S, Noda S, et al. 2013; Long-term results of surgery for papillary thyroid carcinoma with local recurrence. Surg Today. 43(8):848–53. DOI: 10.1007/s00595-012-0353-z. PMID: 23052744.

13. Roh JL, Kim JM, Park CI. 2011; Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia. Ann Surg Oncol. 18(5):1312–8. DOI: 10.1245/s10434-010-1470-9. PMID: 21140230.

14. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, et al. 1992; The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospec-tive review of 1599 patients. J Clin Endocrinol Metab. 75(3):714–20. DOI: 10.1210/jcem.75.3.1517360. PMID: 1517360.

15. Al-Saif O, Farrar WB, Bloomston M, Porter K, Ringel MD, Kloos RT. 2010; Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab. 95(5):2187–94. DOI: 10.1210/jc.2010-0063. PMID: 20332244. PMCID: PMC5399471.

16. Schuff KG. 2011; Management of recurrent/persistent papillary thyroid carcinoma: efficacy of the surgical option. J Clin Endocrinol Metab. 96(7):2038–9. DOI: 10.1210/jc.2011-1663. PMID: 21734006.

17. Yim JH, Kim WB, Kim EY, Kim WG, Kim TY, Ryu JS, et al. 2011; The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. J Clin Endocrinol Metab. 96(7):2049–56. DOI: 10.1210/jc.2010-2298. PMID: 21508143.

18. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, et al. 2004; Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 89(7):3402–7. DOI: 10.1210/jc.2003-031521. PMID: 15240622.

19. Kim WB. 2015; A closer look at papillary thyroid carcinoma. Endocrinol Metab (Seoul). 30(1):1–6. DOI: 10.3803/EnM.2015.30.1.1. PMID: 25827451. PMCID: PMC4384666.

20. Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. 2002; Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol. 178(3):699–704. DOI: 10.2214/ajr.178.3.1780699. PMID: 11856701.

21. Heilo A, Sigstad E, Fagerlid KH, Haskjold OI, Groholt KK, Berner A, et al. 2011; Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab. 96(9):2750–5. DOI: 10.1210/jc.2010-2952. PMID: 21715533.

22. Hay ID, Lee RA, Davidge-Pitts C, Reading CC, Charboneau JW. 2013; Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery. 154(6):1448–54. discussion 54–5. DOI: 10.1016/j.surg.2013.07.007. PMID: 24176579.

23. Guenette JP, Monchik JM, Dupuy DE. 2013; Image-guided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma. J Vasc Interv Radiol. 24(5):672–9. DOI: 10.1016/j.jvir.2013.02.001. PMID: 23622038.

24. Nixon IJ, Angelos P, Shaha AR, Rinaldo A, Williams MD, Ferlito A. 2018; Image-guided chemical and thermal ablations for thyroid disease: review of efficacy and complications. Head Neck. 40(9):2103–15. DOI: 10.1002/hed.25181. PMID: 29684251.

25. Shin JE, Baek JH, Lee JH. 2013; Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol. 25(1):14–9. DOI: 10.1097/CCO.0b013e32835a583d. PMID: 23079931.

26. Lee SJ, Jung SL, Kim BS, Ahn KJ, Choi HS, Lim DJ, et al. 2014; Radiofrequency ablation to treat loco-regional recurrence of well-differentiated thyroid carcinoma. Korean J Radiol. 15(6):817–26. DOI: 10.3348/kjr.2014.15.6.817. PMID: 25469095. PMCID: PMC4248639.

27. Park KW, Shin JH, Han BK, Ko EY, Chung JH. 2011; Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann Surg Oncol. 18(9):2564–8. DOI: 10.1245/s10434-011-1619-1. PMID: 21347777.

28. Kim JH, Baek JH, Lim HK, Ahn HS, Baek SM, Choi YJ, et al. 2018; 2017 thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology. Korean J Radiol. 19(4):632–55. DOI: 10.3348/kjr.2018.19.4.632. PMID: 29962870. PMCID: PMC6005940.

29. Garberoglio R, Aliberti C, Appetecchia M, Attard M, Boccuzzi G, Boraso F, et al. 2015; Radiofrequency ablation for thyroid nodules: which indications? The first Italian opinion statement. J Ultrasound. 18(4):423–30. DOI: 10.1007/s40477-015-0169-y. PMID: 26550079. PMCID: PMC4630279.

30. Perrier ND, Brierley JD, Tuttle RM. 2018; Differentiated and anaplastic thyroid carcinoma: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 68(1):55–63. DOI: 10.3322/caac.21439. PMID: 29092098. PMCID: PMC5766386.

31. Cunha N, Rodrigues F, Curado F, Ilheu O, Cruz C, Naidenov P, et al. 2007; Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. Eur J Endocrinol. 157(1):101–7. DOI: 10.1530/EJE-07-0088. PMID: 17609408.

32. Ahmed M. Technology Assessment Committee of the Society of Interventional Radiology. 2014; Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update: supplement to the consensus document. J Vasc Interv Radiol. 25(11):1706–8. DOI: 10.1016/j.jvir.2014.09.005. PMID: 25442133.

33. Mauri G, Pacella CM, Papini E, Solbiati L, Goldberg SN, Ahmed M, et al. 2019; Image-guided thyroid ablation: proposal for standardization of terminology and reporting criteria. Thyroid. 29(5):611–8. DOI: 10.1089/thy.2018.0604. PMID: 30803397.

34. Suh CH, Baek JH, Choi YJ, Lee JH. 2016; Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer: a systematic review and meta-analysis. Thyroid. 26(3):420–8. DOI: 10.1089/thy.2015.0545. PMID: 26782174.

35. Jeong SY, Baek JH, Choi YJ, Lee JH. 2017; Ethanol and thermal ablation for malignant thyroid tumours. Int J Hyperthermia. 33(8):938–45. DOI: 10.1080/02656736.2017.1361048. PMID: 28797186.

36. Kim SY, Kim SM, Chang H, Kim BW, Lim CY, Lee YS, et al. 2017; Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer. Eur Arch Otorhinolaryngol. 274(9):3497–501. DOI: 10.1007/s00405-017-4660-2. PMID: 28664330.

37. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. 2006; Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg. 244(2):296–304. DOI: 10.1097/01.sla.0000217685.85467.2d. PMID: 16858194. PMCID: PMC1602167.

38. Fontenot TE, Deniwar A, Bhatia P, Al-Qurayshi Z, Randolph GW, Kandil E. 2015; Percutaneous ethanol injection vs reoperation for locally recurrent papillary thyroid cancer: a systematic review and pooled analysis. JAMA Otolaryngol Head Neck Surg. 141(6):512–8. DOI: 10.1001/jamaoto.2015.0596. PMID: 25928119.

39. Tomoda C, Sugino K, Matsuzu K, Uruno T, Ohkuwa K, Kitagawa W, et al. 2016; Cervical lymph node metastases after thyroidectomy for papillary thyroid carcinoma usually remain stable for years. Thyroid. 26(12):1706–11. DOI: 10.1089/thy.2016.0225. PMID: 27616725.

40. Gulcelik MA, Karaman N, Dogan L, Sahiner I, Akgul GG, Kahraman YS, et al. 2017; Radioguided occult lesion localization for locally recurrent thyroid carcinoma. Eur Arch Otorhinolaryngol. 274(7):2915–9. DOI: 10.1007/s00405-017-4563-2. PMID: 28409262.

41. Borso E, Grosso M, Boni G, Manca G, Bianchi P, Puccini M, et al. 2013; Radioguided occult lesion localization of cervical recurrences from differentiated thyroid cancer: technical feasibility and clinical results. Q J Nucl Med Mol Imaging. 57(4):401–11. PMID: 24322795.